Dhar, R., Kirkpatrick, J., Gilbert, L., Khanna, A., Modi, M. M., Chawla, R. K., . . . Gadola, S. D. (2023). Doxycycline for the prevention of progression of COVID-19 to severe disease requiring intensive care unit (ICU) admission: A randomized, controlled, open-label, parallel group trial (DOXPREVENT.ICU). Public Library of Science (PLoS).
Chicago Style (17th ed.) CitationDhar, Raja, et al. Doxycycline for the Prevention of Progression of COVID-19 to Severe Disease Requiring Intensive Care Unit (ICU) Admission: A Randomized, Controlled, Open-label, Parallel Group Trial (DOXPREVENT.ICU). Public Library of Science (PLoS), 2023.
MLA引文Dhar, Raja, et al. Doxycycline for the Prevention of Progression of COVID-19 to Severe Disease Requiring Intensive Care Unit (ICU) Admission: A Randomized, Controlled, Open-label, Parallel Group Trial (DOXPREVENT.ICU). Public Library of Science (PLoS), 2023.